Who owns AKTS?
Institutional ownership of Aktis Oncology Inc. from Form 13F, Q2 2026
114 institutional managers reported holding Aktis Oncology Inc. (AKTS) in Form 13F filings for Q2 2026, with 34,170,226 shares worth $1.1B. The largest reported holder was MPM Bioimpact LLC. Managers that filed both quarters cut a net 870,460 shares (-2.6%). 51 opened new positions and 6 sold out.
- Funds holding
- 114
- Value held
- $1.1B
- New / sold out
- 51 / 6
- Net shares, same filers
- -2.6%
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Largest holders of AKTS
| Fund | Value | Share of 13F holdings | Shares | Move |
|---|---|---|---|---|
| MPM Bioimpact LLC | $156M | 14.2% | 4,835,872 | Unchanged |
| EcoR1 Capital, LLC | $155M | 14.1% | 4,824,469 | Unchanged |
| Blue Owl Capital Holdings LP | $99.0M | 9.0% | 3,070,219 | Trimmed |
| BlackRock, Inc. | $73.4M | 6.7% | 2,278,358 | Added |
| T. Rowe Price Investment Management, Inc. | $66.1M | 6.0% | 2,051,447 | Trimmed |
| Wellington Management Group LLP | $63.4M | 5.8% | 1,966,244 | Trimmed |
| RTW Investments, LP | $51.3M | 4.7% | 1,592,043 | Unchanged |
| Ra Capital Management, L.p. | $42.4M | 3.8% | 1,314,405 | Trimmed |
| Jupiter Topco LLC | $42.4M | 3.8% | 1,314,267 | First report |
| Baker Bros. Advisors LP | $32.1M | 2.9% | 996,351 | Unchanged |
| Octagon Capital Advisors LP | $31.0M | 2.8% | 960,847 | Unchanged |
| Merck & Co., Inc. | $30.7M | 2.8% | 952,844 | Unchanged |
| Vanguard Capital Management LLC | $26.3M | 2.4% | 817,075 | Trimmed |
| Price T Rowe Associates Inc | $24.6M | 2.2% | 763,499 | Trimmed |
| TCG Crossover Management, LLC | $22.5M | 2.0% | 696,560 | New |
| Geode Capital Management, LLC | $16.8M | 1.5% | 520,737 | Added |
| Eventide Asset Management, LLC | $16.3M | 1.5% | 507,000 | Unchanged |
| Avidity Partners Management LP | $15.6M | 1.4% | 484,200 | Trimmed |
| State Street Corp | $15.6M | 1.4% | 484,010 | Added |
| a16z Capital Management, L.L.C. | $13.4M | 1.2% | 415,000 | Unchanged |
| Alyeska Investment Group, L.P. | $9.3M | 0.8% | 290,000 | Unchanged |
| FMR LLC | $9.2M | 0.8% | 285,631 | Trimmed |
| ArrowMark Colorado Holdings LLC | $7.9M | 0.7% | 245,872 | Trimmed |
| Northern Trust Corp | $5.8M | 0.5% | 180,575 | Added |
| Charles Schwab Investment Management Inc | $5.4M | 0.5% | 166,842 | Added |
Share of 13F holdings is each fund's shares as a share of the 34,170,226 AKTS shares all 13F filers reported, not of shares outstanding.
Biggest buyers in Q2 2026
- TCG Crossover Management, LLC New+$22.5M
- BlackRock, Inc. Added+$5.4M
- Barclays PLC Added+$4.6M
- Renaissance Technologies LLC New+$3.1M
- Polen Capital Management LLC New+$2.0M
- Tidal Investments LLC New+$1.8M
- State Street Corp Added+$1.8M
- Raymond James Financial Inc New+$1.6M
- AQR Capital Management LLC New+$1.6M
- Quantinno Capital Management LP New+$1.5M
Biggest sellers in Q2 2026
- Price T Rowe Associates Inc Trimmed-$25.8M
- Avidity Partners Management LP Trimmed-$14.6M
- Wellington Management Group LLP Trimmed-$11.3M
- UBS Group AG Trimmed-$8.2M
- Ra Capital Management, L.p. Trimmed-$6.1M
- FMR LLC Trimmed-$3.2M
- Blue Owl Capital Holdings LP Trimmed-$2.9M
- ArrowMark Colorado Holdings LLC Trimmed-$2.7M
- Driehaus Capital Management LLC Sold out-$2.7M
- Ameriprise Financial Inc Trimmed-$2.7M
The change in shares since the quarter before, adjusted for stock splits and priced at the Q2 2026 value per share. Funds bought $64.4M and sold $88.0M; 27 added and 18 trimmed.
Schedule 13D and 13G filings on AKTS
Owners of more than 5% must file within days, so these can be newer than the 13F data.
- 2026-11-16T. Rowe Price Investment Management, Inc. SCHEDULE 13G filed by Aktis Oncology Inc.Schedule 13G
- 2026-05-14Blue Owl Capital Holdings LP SCHEDULE 13G filed by Aktis Oncology Inc.Schedule 13G
- 2026-01-20MPM BIOVENTURES 2018, L.P. SCHEDULE 13D filed by Aktis Oncology Inc.Schedule 13D
- 2026-01-20EcoR1 Capital, LLC SCHEDULE 13D filed by Aktis Oncology Inc.Schedule 13D
- 2026-01-15ELI LILLY & Co SCHEDULE 13D filed by Aktis Oncology Inc.Schedule 13D
- 2026-01-14VV Manager II, LLC SCHEDULE 13D filed by Aktis Oncology Inc.Schedule 13D
Questions about AKTS ownership
- Who owns AKTS stock?
- 114 institutional investment managers reported AKTS positions in their Form 13F filings for Q2 2026, holding 34,170,226 shares worth $1.1B in total. MPM Bioimpact LLC reported the largest position.
- Are funds buying or selling AKTS?
- In Q2 2026, 51 managers opened new AKTS positions, 27 added, 18 trimmed and 6 sold out. Managers that filed in both quarters sold a net 870,460 shares.
- How current is this AKTS institutional ownership data?
- It covers holdings as of the end of Q2 2026. Managers have 45 days after the quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
From the SEC's Form 13F data sets for Q2 2026: every 13F holdings report, matched to AKTS by CUSIP. Options are left out. AKTS news and filings · AKTS insider trades · Top funds